Sales & Marketing News | pharmaphorum

News

Digital therapeutics firm Akili agrees $34 million takeover

In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti

News

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi

News

Asahi Kasei makes $1.1bn bid to buy Calliditas

Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to expand internationally in healthcare.

News

Nippon Shinyaku’s DMD drug fails confirmatory trial

The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020

News

Lilly ups spend on diabetes, obesity drug production to $9bn

Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian

News

Cytokinetics eyes go-it-alone strategy for aficamten

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financi

Digital therapeutics firm Akili agrees $34 million takeover

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

Asahi Kasei makes $1.1bn bid to buy Calliditas

Nippon Shinyaku’s DMD drug fails confirmatory trial

Lilly ups spend on diabetes, obesity drug production to $9bn

Cytokinetics eyes go-it-alone strategy for aficamten

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks